Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simrit Parmar

Showing results (71-80 of 119) with videos related to

Pageof 12
Sort By:
Cytotherapy|February 1, 2014
Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host diseaseSimrit Parmar, Xiaoying Liu, Shawndeep S Tung, et al.
Bone Marrow Transplantation|September 28, 2018
Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndromePiyanuch Kongtim, Simrit Parmar, Denái R Milton, et al.
JAMA Network Open|September 29, 2020
Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation TherapyChelsea C Pinnix, Jillian R Gunther, Penny Fang, et al.
Leukemia & Lymphoma|October 17, 2015
Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphomaPhilip A Thompson, Travis Perera, David Marin, et al.
Blood Advances|March 24, 2023
Randomized, double-blinded, placebo-controlled trial of allogeneic cord blood T-regulatory cells for treatment of COVID-19 ARDSDouglas E Gladstone, Franco D'Alessio, Christopher Howard, et al.
Oncotarget|November 28, 2018
Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitutionJoshua N Kellner, Eveline M Delemarre, Eric Yvon, et al.
Cancer|May 18, 2017
Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myelomaLauren W Veltri, Denái R Milton, Ruby Delgado, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 26, 2015
Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell TransplantationRyan W Jacobs, Rima M Saliba, Koji Sasaki, et al.
Leukemia & Lymphoma|June 3, 2014
Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myelomaZartash Gul, Qaiser Bashir, Martin Cremer, et al.
Cancer Research|June 8, 2011
Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myelomaHong Yang, Simon N Robinson, Yago Nieto, et al.
Pageof 12

Showing results (71-80 of 119) with videos related to

Sort By:
Pageof 12
Cytotherapy|February 1, 2014
Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host diseaseSimrit Parmar, Xiaoying Liu, Shawndeep S Tung, et al.
Bone Marrow Transplantation|September 28, 2018
Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndromePiyanuch Kongtim, Simrit Parmar, Denái R Milton, et al.
JAMA Network Open|September 29, 2020
Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation TherapyChelsea C Pinnix, Jillian R Gunther, Penny Fang, et al.
Leukemia & Lymphoma|October 17, 2015
Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphomaPhilip A Thompson, Travis Perera, David Marin, et al.
Blood Advances|March 24, 2023
Randomized, double-blinded, placebo-controlled trial of allogeneic cord blood T-regulatory cells for treatment of COVID-19 ARDSDouglas E Gladstone, Franco D'Alessio, Christopher Howard, et al.
Oncotarget|November 28, 2018
Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitutionJoshua N Kellner, Eveline M Delemarre, Eric Yvon, et al.
Cancer|May 18, 2017
Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myelomaLauren W Veltri, Denái R Milton, Ruby Delgado, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 26, 2015
Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell TransplantationRyan W Jacobs, Rima M Saliba, Koji Sasaki, et al.
Leukemia & Lymphoma|June 3, 2014
Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myelomaZartash Gul, Qaiser Bashir, Martin Cremer, et al.
Cancer Research|June 8, 2011
Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myelomaHong Yang, Simon N Robinson, Yago Nieto, et al.
Pageof 12